Sarepta TherapeuticsvsUnitedHealth

SRPT and UNH stock compared: price, dividend, valuation and results, from SEC filings.

SRPT

Sarepta Therapeutics, Inc.

$14.49

Value $1.5B

-0.21%
SRPT's page

UNH

UnitedHealth Group Incorporated

$331.78

Value $301B

-5.36%
UNH's page

Sarepta Therapeutics (SRPT) has a market value of $1.5B and UnitedHealth (UNH) $301B. Over the last year, with dividends, SRPT moved -16.9% and UNH +8.4%. Dividend yield: SRPT none, UNH 2.73%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    SRPT$1.5B

    UNH$301B

    UNH is 198 times SRPT

  • Revenue, 12 months

    SRPT$2.0B

    UNH$450B

    UNH is 230 times SRPT

  • Net income, 12 months

    SRPT-$115M

    UNH$15.9B

  • Operating margin

    SRPT-2.5%

    UNH5.3%

    7.8 points apart

  • ROIC

    SRPT-1.8%

    UNH11.3%

    13.0 points apart

  • P/E

    SRPT–

    UNH19.0

  • Dividend yield

    SRPT0.0%

    UNH2.7%

    2.7 points apart

  • 5-year return

    SRPT-82.1%

    UNH-19.3%

    62.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

SRPT-82.1%

UNH-19.3%

10020020222023202420252026
Returns by period
PeriodSRPTWith dividendsUNHWith dividends
1 year since November 18, 2025-16.9%Price -16.9%+8.4%Price +5.6%
3 years since November 17, 2023-82.6%-44.1% a yearPrice -82.6%-34.2%-13.0% a yearPrice -38.3%
5 years since November 18, 2021-82.1%-29.1% a yearPrice -82.1%-19.3%-4.2% a yearPrice -26.3%
10 years since November 21, 2016-61.5%-9.1% a yearPrice -61.5%+160.0%+10.0% a yearPrice +120.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

SRPTSarepta TherapeuticsUNHUnitedHealth

Valuation

SRPTUNH
Valuation
Price$14.49$331.78
Market value$1.5B$301B
Enterprise value (EV)$1.7B$347B
P/E–19.0
P/E, 5-year median–25.0
P/B1.02.9
EV/EBIT–14.5
Free cash flow yield11.6%7.6%

Results and growth

SRPTUNH
Results and growth
Revenue, 12 months$2.0B$450B
Net income, 12 months-$115M$15.9B
Free cash flow, 12 months$176M$22.8B
Earnings per share, 12 months-$1.37$17.52
Revenue growth, year on year15.6%11.8%
Revenue growth a year, past+32.4%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

SRPTUNH
Margins and returns on capital
Gross margin52.4%88.3%
Operating margin-2.5%5.3%
Net margin-5.9%3.5%
ROIC-1.8%11.3%
ROE-8.0%15.5%

Balance sheet

SRPTUNH
Balance sheet
Cash$879M$28.5B
Total debt$1.2B$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

SRPTUNH
Dividends and buybacks
Dividend yield–2.7%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield1.6%1.8%
Shareholder yield1.6%4.6%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: SRPT or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Sarepta Therapeutics or UnitedHealth?

By market value, UnitedHealth ($301B) is about 198.0 times Sarepta Therapeutics ($1.5B), at today's prices.

How did SRPT and UNH stock do over the last 10 years?

Since November 21, 2016, SRPT's price moved -61.5% and UNH's +120.2%. With dividends: SRPT -61.5% (-9.1% a year), UNH +160.0% (+10.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, SRPT or UNH?

The dividend yield at today's price is none for Sarepta Therapeutics and 2.73% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Sarepta Therapeutics or UnitedHealth?

Over the last twelve months, the net margin was -5.9% for Sarepta Therapeutics and 3.5% for UnitedHealth, and the operating margin -2.5% and 5.3%. Revenue was $2.0B and $450B.

Which is the better investment, Sarepta Therapeutics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.